International Journal of Radiation Oncology, Biology, Physics 1993: Vol 26 Index

7 Pages·1993·2.2 MB·English

AUTHOR INDEX
Volume 26, 1993
Abram, W. P., 845, 907 Byers, R. M., 3 Efird, J. T., 551 Graiff, C., 801
Abuchaibe, O., 859 Byhardt, R. W., 459 Ellis, G. K., 23 Greenberg, H. S., 637
Acker, J. C., 851 Emami, B. E., 321, 459 Greenberg, H., 13
Adams, J. A., 551 Cain, J., 809 Endicott, J., 13 Greenberger, J. S., 831
Ahmad, A., 229 Calais, G., 37 Enneking, W. F., 299 Greer, B. E., 809
Alberti, W., 897 Calvo, F. A., 859 Epstein, J. W., 311 Griffin, T. W., 23, 809
Alvarez-Cienfuegos, J., 859 Cassady, J. R., 253 Escarment, P., 245 Grigsby, P. W., 479, 653
Amar, A., 245 Cassisi, N. J., 73, 751 Eschwege, F., 793 Guillamondegui, O., 3
Amichetti, M., 801 Castaigne, S., 397 Evans, R. G., 445, 649 Gunderson, L. L., 483
Anderson, L. L., 163 Castro, J. R., 291, 613 Ewing, C., 721
Andriole, D., 391 Catalano, R., 469
Ha, C. S., 335, 529
Ang, K. K., 3 Catton, C. N., 203 Fahey, P. P., 869
Hackl, A. G., 891
Anklesaria, P., 831 Cha, S. S., 483 Fein, D. A., 751
Haffty, B., 539
Appelbaum, F. R., 275 Chan, D. K. K., 773 Feldmann, H. J., 111
Hallman, M., 117
Arian-Schad, K. S., 891 Chan, F. L., 787 Fellin, G., 801
Halperin, E. C., 353, 413, 851, 905
Aristu, J., 859 Chan, S. K., 721 Feltes, M., 539
Halpern, H., 721
Armstrong, J., 759 Chapet, S., 37 Fermand, J.-P., 397
Halverson, K. J., 593
Armstrong, J. G., 685, 759 Chatterton, B., 229 Fermé, C., 397
Hamilton, C. S., 869
Asbell, S. O., 239 Chavaudra, N., 793 Figge, D. C., 809
Handl-Zeller, L., 891
Augsburger, J. J., 625 Cheng, A. Y., 311 Fignon, A., 37
Harder, D., 897
Austin-Seymour, M. M., 23 Cheng, C.- W., 883 Fineberg, B., 391
Harrington, P. J., 163
Awan, A., 721 Cheung, F. K., 773 Fischbach, J., 239
Harris, J. R., 183
Azaloux, H., 245 Cheung, Y. K., 787 FitzGerald, T. J., 831, 883
Harrison, L., 759
Azinovic, I., 859 Chiang, C.-S., 643 Fontanesi, J., 619
Hayakawa, K., 407
Aziz, H., 711 Choi, K. N., 653 Fontenla, D., 685 Heidorn, D. B., 637
Choy, D., 787 Foo, M. L., 483
Heimann, R., 759
Bagchi, P., 469 Clarke, J., 845, 907 Foo, W., 773
Hempling, R. E., 607
Baken-Brown, K., 291 Coleman, C. N., 705 Fosmire, H., 253, 373, 883
Henze, G., 413
Baker, T. R., 607 Coleman, R. E., 659 Fowble, B. L., 547, 877
Henzen-Logmans, S. C., 135
Band, V., 81 Comis, R., 469 Fowler, J. F., 353
Herman, T. S., 103
Barnes, P. D., 669 Cooper, J. S., 181 Fowler, W., 469
Hermann, K.-P., 897
Barnett, R. B., 261 Corn, B. W., 513 Fox, K., 155
Hernandez, C., 625
Bastin, K. T., 695 Cox, J. D., 363 Fraass, B. A., 681
Herskovic, A., 459
Batnitzky, S., 649 Curran, Jr., W. J., 239, 469, 653 Francois, H., 245
Hicks, M. L., 607
Beach, L., 347 Cygler, J. E., 261 Frankenthaler, R. A., 3
Ho, J. H. C., 773
Bean, J. M., 391 Friedman, A. H., 147
Hoeckel, M., 631
Beard, C. J., 705 D’Agay, M.-F., 397 Frija, J., 397
Holden, S. A., 103
Bedwinek, J., 675 Dally, M. J., 869 Fuks, Z., 365, 685
Holsti, L. R., 211
Benammar, A., 767 Darr, D., 413 Furmanski, P., 89
Holsti, P., 211
Benk, V. A., 551 Das, I. J., 831, 883
Holt, J. A., 285
Bennett, Jr., C. J., 299 Davis, L., 653 Gadalla, T., 203
Horowitz, M., 229
Bentel, G. C., 659 Deeg, H. J., 275 Galvin, J. M., 513, 877
Horton, J., 239
Binns, W. R., 311 del Regato, J. A., 197 Garcia, D. M., 391, 593
Hoshina, M., 51
Blankstein, K., 469 Denham, J. W., 869 Garden, A. S., 3
Houghton, A., 721
Body, G., 37 Deore, S. M., 601 Garton, G. R., 483
Hiieffel, H., 427
Bolner, A., 801 De Porre, P. M. Z. R., 125 Gaspar, L., 413
Hug, E. B., 67
Boronow, R., 711 Descamps, P., 37 G’Baguidi, R., 245
Hunig, L. R., 217
Bosen, E. H., 851 Dewhirst, M. W., 103 Gely, S., 223
Hunter, K., 869
Bosl, G., 759 Dinshawy, K. A., 601 George, S., 413
Hynynen, K., 253, 373
Bosgq, J., 793 Divoux, S., 897 Georgiou, A., 479, 581
Bougnoux, P., 37 Doggett, R. S., 459 Gillan, S. J., 499
Bourhis, J., 793 Donaldson, S. S., 59, 739 Gisselbrecht, C., 397 Isaacson, S., 239
Boyages, J., 141 Dorie, M. J., 417 Glennon, P., 625
Brady, L. W., 625 Dosmann, M. A., 381 Goepfert, H., 3 Jain, N. L., 321
Brenner, D. J., 171 Drach, G. W., 253 Goitein, M., 551 Janjan, N., 653
Brice, P., 397 Drzymala, R. E., 321 Goodman, M. J., 305 Janot, F., 793
Britten, R. A., 837 Dubois, J. B., 223 Goodman, M. L., 67 Jaszczak, R. J., 659
Brown, B. W., 3 Dunbar, S. F., 491, 669 Goodman, R. L., 877 Johannsen, L., 43
Brown, R., 529, 23 Duncan, W., 203, 373 Gospodarowicz, M. K., 203 Jones, T. D., 817
Buchholz, T. A., 189 Dunphy, E. P., 631 Gosserez, O., 245 Joyce, M., 81
Burman, C., 685 Dunscombe, P. B., 155 Graham, T., 275 Jung, L., 81
XII
Kahn, B., 427 Marks, L. B., 147, 659, 905 Perez, C. A., 311, 391, 479, 567, 581, Schwaibold, F., 513
Kahn, M. G., 321 Marosszeky, B., 141 593 Scott, C., 239, 653
Kajanti, M., 211 Martenson, J. A., 483 Peschel, R. E., 539 Seabury, H., 637
Kallman, R. F., 417 Marty, M., 397 Peters, L. J., 3 Selim, H., 653
Kantorowitz, D. A., 89 Mason, K. A., 643 Petti, P. L., 291 Shah, J., 759
Kaplan, I. D., 705 Masters, J. R. W., 837 Pfeiffer, P., 43 Sham, J. S. T., 787
Kapp, D. S., 891 Matrone, G., 681 Pfister, D., 759 Sherouse, G. W., 659
Kase, K. R., 883 Matsumoto, S., 51 Phillips, T. L., 291, 613 Shibuya, H., 51
Kelleher, D. K., 95 Mattson, K., 125 Philpott, G., 391, 593 Shipley, W. U., 551
Keller, S. M., 469 Mcauley, M., 607 Pinnell, S., 413 Shoji, T., 433
Kessaris, N., 341 McCollough, W. M., 73 Pittman, D. D., 197 Shragge, P. C., 261
Kijewski, P. K., 335, 529 McCormick, D., 845, 907 Piver, M. S., 607, 719 Shrivastava, S. K., 601
Kimler, B. F., 445, 649 McIntyre, J., 783 Podgorsak, M. B., 695 Shulman, H., 275
Kivisaari, L., 117 McLaughlin, P. W., 637 Polishook, A., 759 Simpson, J. R., 239, 593
Klarmann, J., 311 McLlrath, D. C., 483 Poon, Y.F., 773 Sloboda, R. S., 499
Kleinberg, L., 129 McManus, P. L., 551 Pothmann, B., 897 Smitt, M. C., 59
Kleineidam, M., 625 McShan, D. L., 371, 681 Pourquier, H., 223 Sneed, P. K., 653
Klotch, D., 13 Mendenhall, N. P., 73 Powlis, W., 877 Soffen, E. M., 513
Knoop, C., 631 Mendenhall, W. M., 73, 751 Prosnitz, L. R., 659 Solin, L. J., 709
Koh, W.-J., 809 Meyer, D., 619 Purdy, J. A., 321 Sontag, M. R., 659
Kraus, D., 759 Michel, M., 245 Puretz, J. L., 607 Spencer, D. P., 147, 659
Krisch, R., 653 Million, R. R., 73, 187, 299, 751 Spiro, R., 759
Kroll, S. M., 613 Miot, C., 397 Quiet, C., 721 Stea, B., 253
Kriimpelmann, S., 111 Mitsuhashi, N., 407 Quivey, J. M., 613 Stelzer, K. J., 809
Kuske, R. R., 391, 549 Miyata, Y., 433 Stetson, P. L., 637
Kutcher, G., 685 Moe, R. E., 23 Raff, R. F., 275 Storb, R., 275
Kvols, L. K., 483 Mohiuddin, M., 653, 767 Ratoanina, J.-L., 245 Stringer, S. P., 73, 751
Molls, M., 111 Ray, S. K., 147, 659 Strong, E., 759
Lai, P. P., 581 Monge, O. R., 451 Recht, A., 183 Stuecklschweiger, G., 891
Lakier, R., 203 Montgomery, W. W., 67 Reddy, S., 305 Stuschke, M., 111
Lalka, S. G., 305 Morantz, R. A., 445, 649 Reynaud-Bougnoux, A., 37 Suit, H. D., 491
Landmann, C., 217 Mori, T., 433 Ridley, M., 13 Suntharalingam, N., 519
Laneuville, P., 831 Moris, A., 245 Roach, III, M., 721 Sutton, H., 721
Langer, C. J., 469 Morris, M. D., 817 Robb, T., 229 Suzuki, A., 433
Langer, M. P., 335, 529 Morrison, W. H., 3 Robinow, J. S., 483 Suzuki, S., 51
Lansac, J., 37 Moykkynen, K., 211 Rofstad, E. K., 451 Suzuki, T., 433
Law, S. C. K., 773 Muecke, T., 229 Rose, C., 43 Swift, P., 253
Lawrence, T. S., 637 Munro, A. J., 203 Rosenberg, A., 491
Le Floch, O., 37 Murayama, C., 433 Rosenthal, D., 491
Lee, A. W. M., 773, 907 Myerson, R., 593 Rosenzweig, K., 539 Tabor, P., 897
Lee, H. K., 581 Rotman, M., 239, 653, 711 Tai, D., 619
Leibel, S. A., 365, 685 Nagorney, D. M., 483 Rouanet, P., 223 Takahashi, I., 407
Lemarié, E., 37 Nash, S., 469 Roy, J. N., 163 Takahashi, M., 407
Leong, L., 787 Nelson, D. F., 239 Rubin, P., 1, 195, 239, 379, 565, 737 Takeda, M., 51
Lepage, E., 397 Nelson, J. S., 239 Rubin, S., 721 Tamimi, H. K., 809
Leszezynski, K., 155 Nguyen, N., 637 Rudoltz, M. S., 767 Tanabe, Y., 433
Levendag, P. C., 125 Niibe, H., 407 Rush, C., 593 Tapson, V., 659
Levy, J., 593 Nishio, A., 433 Russell, A. H., 809 Tarbell, N. J., 669
Lichter, A. S., 681 Nori, D., 341 Russell, K. J., 809 Taskinen, E., 117
Ling, C. C., 163 Northey, S., 103 Russo, A., 229 Taylor, M. E., 593
Litwin, S., 469 Rutishauser, G., 217 Teicher, B. A., 103
Liu, C., 445 Okada, N., 51 Thaw, M., 773
Livingston, R. B., 23 Okunieff, P., 631 Sack, H., 111 Thomadsen, B. R., 695
Lockett, M. A., 581 Oleson, J. R., 365 Sager, E. M., 451 Thomas, G. M., 545
Logsdon, M. D., 581 Olsen, L. A., 459 Sagerman, R. H., 713 Thompson, H. J., 89
Loose, S., 155 Olsen, N. K., 43 Sakaguchi, M., 433 Timms, I., 141
Luboinski, B., 793 Oswald, M. J., 3 Sakakeeny, M. A., 831 Trailins, A. H., 197
Lyng, H., 451 Santucci, M. A., 831 Treurniet-Donker, A. D., 135
Pajak, T. F., 459 Sarin, R., 601 Trotti, A., 13
Maasilta, P., 117 Pani, G., 801 Sato, C., 433 Tucker, G., 593
Mac Manus, M. P., 845, 907 Papadopoulos, D., 539 Sause, W. T., 653 Tung, S. Y., 773
Malaise, E. P., 793 Pardo, F., 859 Saw, C. B., 519 Turgeon, V., 37
Malkin, M. G., 129 Parsons, J. T., 73, 751 Scharl, A., 285 Turkington, T. G., 659
Maluta, S., 801 Patchell, R. A., 347 Schlenger, K., 631 Turner, D. A., 147
Mancini, W. R., 637 Peacock, J. H., 837 Schmidt, W., 427 Turner, S., 141
Mankin, H., 491 Pearcey, R. G., 499 Schoenthaler, R., 291
Maor, M. H., 3 Pelton, J. G., 23 Schroeder, H., 43
Marcus, Jr., R. B., 299 Pepe, M., 275 Schuening, F. G., 275 Urie, M. M., 551
XIll
Valdagni, R., 801 Walsh, D. L., 607 Weinstein, A. S., 239 Xu, S., 619
Van der Kogel, A. J., 713 Wandl, E., 427 Wheat, J., 869
Van Dyk, J., 261 Wang, C. C., 67, 189, 783, 903 Wibault, P., 793
Yeoh, E., 229
van Geel, B. N., 135 Wara, W., 721 Wijnmaalen, A., 135
Young, A. B., 347
van Heerden, J. A., 483 Warde, P., 203 Willett, C. G., 551
Young, R. W., 817
van Ooijen, B., 135 Warenius, H. M., 837 Wilson, G., 793
Van Putten, W. L. J., 125 Wazer, D. E., 81 Wilson, L., 539
Vaupel, P. W., 95, 631 Weaver, K. A., 613 Withers, H. R., 643 Zagars, G. K., 381, 549
Vijayakumar, S., 721 Weber, R. S., 3 Wong, J. W., 311 Zaghoul, M. S., 417
Wechsler-Jentzsch, K., 427 Wong, S., 691 Zelefsky, M. J., 365
Wallace, III, H. J., 809 Weeks, K. J., 147 Woo, M. K., 691 Zelefsky, M., 685, 759
Wallner, K. E., 129, 163 Weichselbaum, R., 721 Wu, A., 519 Zimmerman, S., 245
SUBJECT INDEX
Volume 26, 1993
A Irradiation, 877 Combined modality(ies), 417, 859
Breast conservation, 391 Therapy, 397, 469, 739
Surgery, 675 Comedocarcinoma, 391
Absorption, 229 Bronchoalveolar lavage, 117 Commissioning, 261
Accelerated fractionation, 13 Comparison, Device, 111
Irradiation, 459 Complications
Acid C Late, 601
Ascorbic, 413 Late radiation-induced, 773
Bile, 229 Radiotherapy, 767
Acquired resistance, 837 Cancer Computed tomography, 451, 787
Acute radiation reaction, 417 Advanced-vulvar, 809 Computer
Adenocarcinoma, 631 Breast, 23, 37, 43, 89, 135, 391, 539, 593, Controlled radiation therapy, 335
Pancreatic ductal, 483 601, 883 Treatment planning, 529
Prostate, 253 Cervical, 407 Concomitant boost irradiation, 459
Adjuvant irradiation, 483 Colorectal, 859 Concurrent
Advanced vulvar cancer, 809 Endometrial, 607 Chemoradiotherapy, 469
Afterloading, 347 Intraductal breast, 391 Radiotherapy and chemotherapy, 809
High dose rate, 695 Larynx, 759 Conformal
Remote, 499 Locally advanced non-small cell lung, 469 Radiation therapy, 685
Aggressive reirradiation, 773 Lung, 335, 685 Therapy, 551
Amifostine (WR-2721), 407 Non-small cell, 117 Conjuntiva, 59
Analog, 2-nitroimidazole nucleoside, 433 Non-small cell lung, 459 Conservation, Breast, 391
Analysis Noninvasive breast, 391 Conservative treatment, 37
Decision, 321 Pediatric, 739 Contours, 681
Multivariate, 751 Prostate, 217, 539, 551 Contrast enhancement, 451
Portal film, 869 Recurrent colorectal, 859 Control
Anaplastic carcinoma, 125 Tongue, 51 Local, 125, 601
Anemia in cancer, 721 Canine model, 275 Rates, 613
Angiosarcoma, 135 Carcinogenesis, Mammary, 89 Tumor, 171
Arm edema, 593 Carcinoma, 783 Conventional radiotherapy, 793
Artery, 305 Anaplastic, 125 Cosmesis, 601
Ascorbic acid, 413 Breast, 81, 451 Craniospinal irradiation, 357, 669
Associated regional/distant failures, 773 Cervical, 513 Cyclophosphamide, 417
Aziridinylbenzoquinone (AZQ), 445 Ductal in situ, 391 Cytotoxic therapy, 43
Endometrial, 223
B Nasopharyngeal, 787
Prostate, 211
Recurrent nasopharyngeal, 773
bcr/abl, 831 Cartilage involvement, 73
Beam visualization, 691 Cataract, 625
Bile acid, 229 Cell(s) Decision analysis, 321
Biological dose, 353 Kinetics, 817 Desmoid tumor, 851
Blood Stem, 171, 817 Device comparison, 111
Flow, 95 Stroma, 817 Digitizer, 681
Transfusion, 721 Central nervous system seeding tumors, 669 Disease
Bone neoplasms, 299 Cervical Gorham’s, 491
Boost field localization, 675 Cancer, 407 Hodgkin’s, 397, 739
Brachial plexopathy, 43 Carcinoma, 513 Dose
Brachytherapy, 51, 245, 347, 353, 519, 613, Lymph-nodes, 801 Biological, 353
619, 625, 695 Cervix, 479 Calculations, 261
Gynecological, 341 Charged particles, 291 Inhomogeneity, 163
High dose-rate, 891 Chemoprotection, 417 Optimization, 3, 499
Intravaginal, 499 Chemotherapy, 23, 445, 759 Per fraction, 601
Low-dose-rate, 513 Induction, 37 Remembered, 643
Brain, 347 Chest wall irradiation, 877 Transit, 695
Metastases, 653 Chordoma, 291 Dose-rate, 601
Brain tumor, 129 Chronic Pulse, 353
High-grade, 649 Myelogenous leukemia, 831 Dose-volume
Brd/Urd, 637 Radiation injury, 407 Histogram, 335, 551, 883
Breast cancer, 23, 37, 43, 89, 135, 391, 539, Cis-platinum, 445 Limits, 529
593, 601, 883 Cisplatin, 417, 801 Dosimetry, 897
Intraductal, 391 Clinical trial, 613 Radiation, 519
Noninvasive, 391 CNS tumors, 845 TLD in vitro, 341
Breast Cobalt-60 eye plaques, 625 TLD in vivo, 341
Carcinoma, 81, 451 Collateral resistance, 837 DS-sarcoma, 95
Conserving therapy, 135 Colorectal cancer, 859 Ductal carcinoma in situ, 391
Edema, 593 Recurrent, 859 Dural sac, 669
XV
E H.D.R., 347 K
Head and neck, 13
Neoplasms, 3
EDs, 643 Tumors, 801 Karnofsky performance status, 129
Edema Helium, 291 Keloid, 245
Arm, 593 High dose rate
Breast, 593 Afterloader, 341
Effects Afterloading, 695
Late, 649, 739 Brachytherapy, 891
Radiation, 305 High-grade brain tumor, 649
Elapsed treatment days, 767 Histogram(s)
EMT6 tumor, 433 Dose volume, 335, 551, 883 Labeling index, 793
Endometrial Volume and surface dose, 163 Larynx, 783
Cancer, 607 Hodgkin’s disease, 397, 739 Cancer, 759
Carcinoma, 223 Hot water hyperthermia system, 891 Preservation, 759
Endometrium, 479 Human cell lines, 837 Laser Doppler flowmetry, 95
Episcleral plaques, 613 Hyperfractionation, 417 Late
Error(s) Hyperthermia, 253, 451, 801 Complications, 601
Radiotherapy treatment, 869 Hot water system, 891 Effects, 649, 739
Setup, 883 Interstitial, 891 Radiation-induced complications, 773
Erythropoietin, 721 Transrectal ultrasound, 253 Latency, 643
Etanidazole, 433 Hypopharyngeal neoplasms, 751 Local control, 125, 601, 767
Evaluation, 321 Hypoxia, 631 Locally advanced non-small cell lung cancer,
Implant, 163 Hypoxic cells, 433 469
Excision cavity demarcation, 675 Long-term local control and survival, 773
Exclusive radiation treatment, 223 Low dose rate, 353, 637
Extent of resection, 239 Brachytherapy, 513
External beam radiation, 539 Lung cancer, 335, 685
Therapy, 125 Locally advanced non-small cell, 469
Extracapsular extension, 13 Non-small cell, 117, 459
Eye plaques, 897 Lung injury, 659
Cobalt-60, 625 Lymph-nodes
Eye-equivalent phantom material, 897 IL-1, 417 Cervical, 801
Protection, 417 Paraaortic, 607
Imaging Lymphoma, 59
Fiber-optic, 311
Magnetic resonance, 669
Implant(s)
Evaluation, 163
Factors
Interstitial, 519
Prognostic, 3
Permanent, 163
Technical, 581
In vitro TLD dosimetry, 341 Magnetic resonance imaging, 669
Fiber-optic imaging, 31 1
In vivo TLD dosimetry, 341 Malignancy, 141
Fibromatosis, 851
Induction chemotherapy, 37 Malignant glioma(s), 539, 637
Field matching, 691
Inhomigeneity, Dose, 163 Mammary carcinogenesis, 89
Field placement accuracy, 155
Injury Marrow toxicity, 275
5-fluorouracil, 417
Flunarizine, 103 Chronic radiation, 407 Matched peripheral dose (MPD), 163
Fluosol®, 649 Lung, 659 Medulloblastoma, 357
Fluosol-DA, 103 Residual, 643 Melanoma, 619
Fraction size, 767 Interleukin-1, 417 Uveal, 613, 625
Interstitial Metastases(is), 125
Fractionation, Accelerated, 13
Hyperthermia, 891 Brain, 653
Implants, 519 Neck node, 759, 787
G Intracavitary gynecologic applicator, 513 Multivariate
Intracranial, 445 Analysis, 751
Intraductal breast cancer, 391 Utility theory, 321
Intraoperative radiotherapy, 859 Myelopathy, 643
Gastrointestinal transit, 229 Intravaginal Myelopoiesis, 817
Genetics, 739
Brachytherapy, 499
Geriatric cancer population, 539
Radiation, 341
Giant cell tumor, 299
Inverted papilloma, 67
Glioblastoma, 239
lodine-125, 613, 619
Glioma(s), 129
Seeds, 897
Malignant, 539, 637
IORT, 859
Gorham’s disease, 491
Irradiation Nasal
Granulocyte-colony stimulating factor, 845
Accelerated fractionation, 459 Cavity, 67
Growth regulation, 81
Adjuvant, 483 Squamous cell carcinoma of vestibule, 73
Gynecological brachytherapy, 341
Breast, 877 Nasopharyngeal carcinoma, 787
Chest wall, 877 Neck node metastases, 759, 787
Concomitant boost, 459 Neon, 291
H
Craniospinal, 357, 669 Neoplasm(s)
Prophylactic mediastinal, 381 Bone, 299
Proton, 551 Head and neck, 3
Half-times of repair, 353 Tangential field, 877 Hypopharyngeal, 751
Halogenated pyrimidines, 637 Total body, 275 Oropharyngeal, 751
Neuropathy, 479 Chronic injury, 407 Seminoma, 381
Neutrons, 837 Dermatitis, 413 Sequencing, 23
Neutropenia, 845 Dosimetry, 519 Setup error, 883
Nicotinamide, 95 Effects, 305 Simulated annealing, 499
Nitroprusside, 103 Enteritis, 229 Simulation, 691, 883
Non-small cell lung cancer, 117, 459 External beam, 539 Single photon emission tomography perfu-
Noninvasive breast cancer, 391 Intravaginal, 341 sion scan (SPECT), 659
Nonlinear least squares regression, 147 Radical thoracic, 469 Sinuses, Paranasal, 67
Recovery, 817 Small intestine, 229
O Rectal tolerance, 551 Spinal cord, 643
Sensitizer(s), 631, 637 Compression, 141
Therapeutic, 89 Split-course radiotherapy, 211
Ocular, 619 Radiation therapy, 67, 73, 141, 223, 305, Spontaneous regression, 491
413, 417, 491, 519, 593, 607, 631, Squamous cell carcinoma of the nasal vesti-
1-methyl-I-nitrosourea, 89
653, 685, 759 bule, 73
On-line image verification, 311
Optimization, 529 Computer controlled, 335 Stage III NSCLC, 469
Dose, 3, 499 Conformal, 685 Stem cell(s), 171, 817
Orbit, 59 External beam, 125 Stereotaxic, 347
Oropharyngeal neoplasms, 751 Pediatric, 739 Stomach, 229
Oropharynx, 793 Treatment planning, 681 Stroma cell, 817
Osteolysis, 491 Radiation treatment, 883 Surgery, 491
Overall treatment time, 21 1 Exclusive, 223 Breast conservation, 675
Oxygen, 649 Radical thoracic radiation, 469 Surgical clips, 675
Oxygenation, 95, 721 Radioactive halo-estrogen, 285 Survival, 125, 767
Radioprotection, 407, 417 Swine, 285
Radiosensitivity, 81, 831
P
Radiosensitization, 103
Radiosensitizers, 433
Radiosurgery, 147
Pancreatic ductal adenocarcinoma, 483
Radiotherapy, 43, 59, 117, 245, 299, 357,
Paraaortic lymph nodes, 607
381, 391, 445, 649, 751, 817, 845, 851
Paranasal sinuses, 67
Complications, 767
Patterns of failure, 483
Conventional, 793
Pediatric
Intraoperative, 859 Tamoxifen, 89
Cancer, 739
Postoperative, 3, 13 Tangential field irradiation, 877
Radiation therapy, 739
Split-course, 211 Technical factors, 581
Perfluorochemical emulsion, 649
Treatment errors, 869 Therapeutic radiation, 89
Peripheral vascular escape, 285
Rat brain tumor, 445 Therapy
Permanent implant, 163
Rate Breast-conserving, 135
Photones, 837
High dose afterloading, 695 Combined modality, 397, 469, 739
Plaques
Low dose, 353, 637 Conformal, 551
Cobalt-60 eye, 625
Pulse dose, 353 Cytotoxic, 43
Episcleral, 613
Rats, 417 External beam radiation, 125
Eye, 897
Rectal radiation tolerance, 551 Pediatric radiation, 739
Plexopathy, 479
Recurrent Radiation, 67, 73, 141, 223, 305, 413,
Pneumonitis, 593
Colorectal cancer, 859 417, 491, 519, 581, 593, 607, 631,
Portal
Nasopharyngeal carcinoma, 773 653, 685, 759
Film analysis, 869
Regional Thermal parameters, 891
Verification, 155
Hyperthermia, 111 Three-dimensional (3-D)
Positive margins, 13
Node recurrence, 593 Radiation treatment planning, 321
Postoperative radiotherapy, 3, 13
Reirradiation, 291, 783 Treatment planning, 147, 685
Potential doubling time, 793
Aggressive, 773 Thyroid, 125
Predictive assay, 451
Relative effectiveness, 353 Tongue cancer, 51
Prognosis, 217
Remembered dose, 643 Total body irradiation, 275
Prognostic factors, 3
Remote afterloading, 499 Toxicity, 111, 417, 445
Prophylactic mediastinal irradiation, 381
Reossification, 491 Marrow, 275
Prostate, 581
Resection, Transurethral, 217 Transit dose, 695
Adenocarcinoma, 253
Residual injury, 643 Transrectal ultrasound hyperthermia, 253
Cancer, 217, 539, 551
Resistance, Collateral, 837 Transurethral resection, 217
Carcinoma, 211
Results of treatment, 73 Treatment
Proton irradiation, 551
Retinoblastoma, 739 Conservative, 37
Pulse dose rate, 353
Re-treatment, 643 Exclusive radiation, 223
Pyrimidines, Halogenated, 637
Rhabdomyosarcoma, 739 Outcome, 751
RP-170, 433 Overall time, 211
Q
RP-343, 433 Radiation, 883
Results, 73
Verification, 311
Quality assurance, 261, 869
Treatment planning
Computer(s), 261, 529
R Radiation therapy, 681
Sacrum, 291 Three-dimensional, 147, 685
SCCVII tumor, 433 Three-dimensional radiation, 321
Rabbit, 285 Seed(s) Tumor and normal tissue temperatures, 111
Radiation, 23, 129, 291, 479, 643, 659, 801 Iodine-125, 897 Tumor(s)
Acute reaction, 417 Localization, 163 Brain, 129
XVII
Central nervous system seeding, 669 Site, 239 Vv
CNS, 845 Size, 239
Control, 171 Volume, 171 Vasculature, 305
Desmoid, 851 Two 2-nitroimidazole nucleoside analog, 433 Verification
EMT6, 433 On-line image, 311
Giant cell, 299 Portal, 155
Head and neck, 801 Treatment, 311
High-grade brain, 649 Vertebral growth, 417
Perfusion, 103 Visual outcome, 613
Protection, 407 Vitamin C, 413
Rat brain, 445 Vocal cord carcinoma (early stage), 767
SCCVII, 433 Uveal melanoma, 613, 625 Volume and surface dose histograms, 163